Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.30 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.30 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL662271 | 0.87 | CA12 (0.39) | TSHRCA12CA1CA2CA9 | |
| SCHEMBL301287 | 0.73 | — | — | |
| SCHEMBL6347666 | 0.73 | — | — | |
| SCHEMBL3884 | 0.71 | TSHR (0.48) | TSHRCYP2A6MAOAMAOB | |
| SCHEMBL286696 | 0.71 | TSHR (0.48) | TSHRCYP2A6MAOAMAOB | |
| SCHEMBL7063876 | 0.67 | TSHR (0.63) | TSHRCA12CA1CA2CA9 | |
| Fluoride SCHEMBL31607698 | 0.67 | TSHR (0.48) | TSHRCYP2A6MAOAMAOB | |
| SCHEMBL24772918 | 0.66 | TSHR (0.60) | TSHRCA12CA1CA2CA9 | |
| SCHEMBL24774025 | 0.66 | TSHR (0.60) | TSHRCA12CA1CA2CA9 | |
| Fluoride SCHEMBL9776698 | 0.66 | TSHR (0.80) | TSHRCYP2A6MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092554-A1 | 1,3,5 TRI-SUBTITUTED BENZENES FOR TREATMENT OF ALZHEIMER'S DISEASE AND OTHER DISORDERS | ENVIVO PHARMACEUTICALS, INC. | 2011-04-21 | — | — | US | disclosed |
| WO-2009137503-A1 | HDAC INHIBITORS AND USES THEREOF | ENVIVO PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009137499-A1 | INHIBITORS OF HISTONE DEACETYLASE | ENVIVO PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009067493-A2 | 1,3,5 TRI-SUBTITUTED BENZENES FOR TREATMENT OF ALZHEIMER'S DISEASE AND OTHER DISORDERS | ENVIVO PHARMACEUTICALS, INC. (US) | 2009-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092554-A1 | 1,3,5 TRI-SUBTITUTED BENZENES FOR TREATMENT OF ALZHEIMER'S DISEASE AND OTHER DISORDERS | PSEN1, PSEN2, BACE1 | TSHR 2879/4885CA12 3215/4885CA1 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.